NASDAQ:VVUS - VIVUS Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.09 -0.04 (-1.88 %) (As of 02/27/2020 08:31 AM ET) Add Compare Today's Range$2.05Now: $2.09▼$2.1950-Day Range$2.09MA: $2.60▼$3.3852-Week Range$2.05Now: $2.09▼$5.24Volume209,911 shsAverage Volume1.93 million shsMarket Capitalization$22.24 millionP/E RatioN/ADividend YieldN/ABeta1.7 ProfileAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email VIVUS, Inc operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:VVUS Previous Symbol CUSIP92855110 CIK881524 Webhttp://www.vivus.com/ Phone650-934-5200Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$65.06 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value($3.77) per share Price / Book-0.55Profitability EPS (Most Recent Fiscal Year)($3.48) Net Income$-36,950,000.00 Net Margins-40.56% Return on EquityN/A Return on Assets-10.68%Miscellaneous Employees57 Outstanding Shares10,640,000Market Cap$22.24 million Next Earnings Date3/3/2020 (Confirmed) OptionableOptionable Receive VVUS News and Ratings via Email Sign-up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VVUS Rates by TradingView VIVUS (NASDAQ:VVUS) Frequently Asked Questions What is VIVUS's stock symbol? VIVUS trades on the NASDAQ under the ticker symbol "VVUS." When did VIVUS's stock split? How did VIVUS's stock split work? VIVUS's stock reverse split on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split. How were VIVUS's earnings last quarter? VIVUS, Inc. (NASDAQ:VVUS) issued its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.30. The biopharmaceutical company earned $17.97 million during the quarter, compared to analyst estimates of $19.13 million. View VIVUS's Earnings History. When is VIVUS's next earnings date? VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for VIVUS. How can I listen to VIVUS's earnings call? VIVUS will be holding an earnings conference call on Tuesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. Has VIVUS been receiving favorable news coverage? News headlines about VVUS stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VIVUS earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for VIVUS. Are investors shorting VIVUS? VIVUS saw a increase in short interest in February. As of February 14th, there was short interest totalling 749,400 shares, an increase of 12.6% from the January 30th total of 665,300 shares. Based on an average trading volume of 609,600 shares, the short-interest ratio is currently 1.2 days. Currently, 8.0% of the shares of the stock are sold short. View VIVUS's Current Options Chain. Who are some of VIVUS's key competitors? Some companies that are related to VIVUS include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX). What other stocks do shareholders of VIVUS own? Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Novavax (NVAX), Inovio Pharmaceuticals (INO), Melinta Therapeutics (MLNT), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Arena Pharmaceuticals (ARNA), BioCryst Pharmaceuticals (BCRX) and Geron (GERN). Who are VIVUS's key executives? VIVUS's management team includes the folowing people: Mr. John P. Amos, CEO & Director (Age 52)Mr. Kenneth Suh, Pres (Age 43)Mr. Mark K. Oki, Sr. VP, CFO & Chief Accounting Officer (Age 50)Mr. John L. Slebir, Sr. VP of Bus. Devel., Gen. Counsel & Sec. (Age 54)Dr. Santosh T. Varghese, Chief Medical Officer (Age 49) How do I buy shares of VIVUS? Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is VIVUS's stock price today? One share of VVUS stock can currently be purchased for approximately $2.09. How big of a company is VIVUS? VIVUS has a market capitalization of $22.24 million and generates $65.06 million in revenue each year. The biopharmaceutical company earns $-36,950,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. VIVUS employs 57 workers across the globe.View Additional Information About VIVUS. What is VIVUS's official website? The official website for VIVUS is http://www.vivus.com/. How can I contact VIVUS? VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected] MarketBeat Community Rating for VIVUS (NASDAQ VVUS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 363 (Vote Outperform)Underperform Votes: 428 (Vote Underperform)Total Votes: 791MarketBeat's community ratings are surveys of what our community members think about VIVUS and other stocks. Vote "Outperform" if you believe VVUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VVUS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/27/2020 by MarketBeat.com StaffFeatured Article: What is the Gross Domestic Product (GDP)?
